NCT06465329 2026-02-12
A Study of Cemiplimab Plus Chemotherapy Versus Cemiplimab Plus Chemotherapy Plus Other Cancer Treatments for Adult Patients With Operable Non-Small Cell Lung Cancer (NSCLC)
Regeneron Pharmaceuticals
Phase 2 Recruiting
Regeneron Pharmaceuticals
Incyte Corporation
Hoffmann-La Roche
GlaxoSmithKline